LL-37 Research: Trials, Data & What the Studies Show
LL-37 is the only cathelicidin antimicrobial peptide made by the human body. The published work is largely animal-tissue and human cell-culture data. It shows powerful antimicrobial and wound-healing findings alongside well-documented autoimmune and tumour-growth signals that researchers also track.
Mechanism of action
LL-37 is a 37-amino-acid, amphipathic alpha-helical peptide cleaved from the hCAP18 precursor protein by neutrophils and epithelial cells when the body detects a threat. It is the only known naturally occurring human cathelicidin.
Membrane attack: the peptide is strongly positively charged (cationic) and has both water-loving and fat-loving faces. It seeks out the negatively charged lipid membranes of invading bacteria, wraps around them and physically drills pores through the cell wall — via a toroidal-pore or carpet mechanism — causing the bacterium to burst.
Immune signalling: beyond killing pathogens, LL-37 binds formyl peptide receptor 2 (FPR2) and physically recruits neutrophils, monocytes and T-cells to the site of infection or injury. This immunomodulatory role, not raw bacterial killing, is what most current research focuses on.
The studies
The LL-37 evidence base is peer-reviewed animal tissue work and human cell-culture data rather than large randomised human trials. Each study below states the benefit that was tested, then what the data actually showed. The research-context section at the end is drawn from the same published literature.
Endotoxin & sepsis
Neutralising toxic shock (LPS detoxification)
Benefit tested: can LL-37 bind directly to lipopolysaccharide (LPS) endotoxins to prevent septic shock and clear them safely from the bloodstream?
In vivo animal model of severe endotoxaemia · survival, cytokine release and structural protection endpoints
- Confirmed
- LPS endotoxin neutralisation
- Sharply blunted
- TNF-α and IL-6 release
- Improved
- Survival in endotoxaemia
Benefits shown in the data
- Physically binds and wraps around LPS toxins so they cannot reach the TLR4 immune receptor that triggers the shock cascade.
- Cuts the release of the lethal inflammatory markers TNF-α and interleukin-6.
- Improved survival rates in animals exposed to severe endotoxin loads.
- When Gram-negative bacteria die they dump LPS endotoxins, which can crash blood pressure and cause fatal septic shock. LL-37 intercepts that step rather than killing more bacteria.
- The protective effect is anti-inflammatory, not sedative or antibiotic — it works by blocking receptor recognition of the toxin.
- This is animal-model data. No human sepsis outcome trial supports it.
Wound repair
Wound healing and angiogenesis (new blood-vessel growth)
Benefit tested: can synthetic LL-37 stimulate the growth of new blood vessels and accelerate closure of the skin in wounds that will not heal?
Cellular and tissue-mapping work tracking VEGF expression, endothelial branching and keratinocyte proliferation in human skin models
- Cascading increase
- VEGF expression
- Rapid
- New vessel branching
- Increased
- Keratinocyte proliferation
Benefits shown in the data
- Triggers a release of vascular endothelial growth factor (VEGF) by binding FPR2 receptors on endothelial cells — the signal that builds new blood supply.
- Drives rapid branching of new blood vessels into tissue that was previously under-perfused.
- Pushes keratinocytes (skin cells) to multiply and physically close the wound bed.
- Chronic wounds such as diabetic ulcers stall because they lack blood supply and cell-migration signalling. LL-37 addresses both of those at once in these models.
- The effect is a genuine growth signal, not simply infection control.
- Note the trade-off: the same pro-growth, pro-angiogenic activity is the reason for the tumour warning further down this page.
Chronic infection
Breaking down hard-to-kill biofilms
Benefit tested: can LL-37 penetrate and dissolve protective bacterial biofilms at concentrations low enough to leave human cells unharmed?
In vitro assay tracking formation and degradation of Pseudomonas aeruginosa biofilm matrices across a concentration range
- Sub-lethal
- Effective concentration
- Prevented
- Biofilm formation
- Gene down-regulation
- Mechanism
Benefits shown in the data
- Prevents biofilm formation at extremely low concentrations — well below the level needed to kill bacteria outright, and below the level that damages human cells.
- Down-regulates the genetic machinery bacteria use to stick together and build their protective slime shield.
- Leaves the sheltered bacteria exposed so the body's own immune system can clear them.
- Bacteria inside a biofilm can be up to 1,000 times more resistant to conventional antibiotics, which is why chronic infections persist.
- LL-37 works by disarming the shield rather than out-muscling it, which is why such small amounts are effective.
- This is laboratory culture work on Pseudomonas aeruginosa; it does not establish clinical infection outcomes.
Respiratory & mucosal
Chronic sinus and respiratory infection tissue data
Benefit tested: does raising local LL-37 levels help clear stubborn, treatment-resistant chronic rhinosinusitis?
Tissue biopsy evaluations mapping cathelicidin presence in patients with severe chronic sinus inflammation versus healthy mucosa
- Deficient
- Native LL-37 in patients
- Restored
- Mucosal antimicrobial capacity
- Reduced
- Mucus viscosity
Benefits shown in the data
- Identified a real, measurable deficiency: chronic sinusitis patients produce structurally less LL-37 than healthy controls.
- Restoring the peptide restored the mucosal layer's innate ability to destroy invading microbes.
- Helped break up the thick, sticky mucus that keeps these infections cycling.
- The sinuses and lungs rely on natural antimicrobial peptides to stay sterile, so a cathelicidin deficit is a plausible root cause rather than a coincidence.
- This work is descriptive tissue mapping plus supplementation response — not a randomised treatment trial.
Storage & handling
LL-37 is supplied as a lyophilised powder. Keep sealed vials refrigerated or frozen, protected from light and moisture.
Reconstitute with bacteriostatic water added slowly down the inner wall of the vial; swirl gently until dissolved and never shake — this peptide's alpha-helical structure is sensitive to mechanical stress.
Store reconstituted solution at 2-8 °C, protect from light, and use within your lab's defined stability window. Avoid repeated freeze-thaw cycles.
LL-37 research context
LL-37 is a potent candidate for acute infection and deep wounds in research models. The same properties that drive its benefits also produce signals that researchers monitor closely in the peer-reviewed literature.
Autoimmune signalling
LL-37 binds tightly to stray fragments of DNA. Those complexes can activate pattern-recognition immune pathways. This mechanism is being studied in psoriasis, rosacea and rheumatoid arthritis models because it may help initiate or amplify autoimmune responses.
Tumour-growth signalling
The pro-growth, pro-angiogenic properties that make LL-37 interesting for wound healing are also being studied in tumour biology. Tissue studies report that certain cancers, notably ovarian, lung and breast carcinomas, can co-opt LL-37 signalling to support growth and spread.
All information on this page is provided for laboratory and educational reference only. Peptides Lab SA (PTY) Ltd supplies compounds strictly for in-vitro research use. Nothing here is medical advice, a dosing recommendation, or a claim of human safety or efficacy.